title: ExonHit Therapeutics.
abstract: ExonHit Therapeutics' mission is to be the leader in the application of alternative RNA splicing to the discovery and development of therapeutics and diagnostics for cancer and neurodegenerative diseases. The most advanced drugs in the Company's pipeline are treatments for amyotropic lateral sclerosis. One of these drugs entered Phase II trials in October 2002 and the other is planned for Phase I trials in 2003. Compounds for treating cancer are currently in the preclinical stage. ExonHit is also engaged in the discovery of molecular pharmacogenomic and diagnostic tests derived from RNA splicing events. ExonHit has established alliances with leading pharmaceutical and diagnostics companies, accelerating the R&D programs of its partners. The Company intends to license its pipeline of high-value drugs (after Phase IIb clinical trials) and diagnostics to these and other global partners.
authors.affiliation: ExonHit Therapeutics, Inc., 217 Perry Parkway, Suite 5, Gaithersburg, MD 20877, USA. jim.lyddy@exonhit-usa.com
authors.forename: Jim
authors.initials: J
authors.lastname: Lyddy
mesh_terms: D005091:Exons / Q000187:drug effects / Q000235:genetics; D006801:Humans; D013678:Technology, Pharmaceutical / Q000331:legislation & jurisprudence / Q000379:methods* / Q000639:trends